WillItSurvive
Pharma and healthcare groups · United States

Alnylam Pharmaceuticals

alnylam.com ↗

Biotech that sells FDA-approved RNAi drugs silencing disease-causing genes.

Hard to displace
Assessed 24 July 2026 · Evidence as of 24 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 24 July 2026 · Checkable from July 30, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report
The call

Alnylam's approved RNAi drugs face no shipped rival in their main disease, but nearly all its revenue leans on one franchise now under payer pricing pressure.

Alnylam sells prescription medicines that use RNA technology to treat rare diseases like a heart and nerve condition called ATTR. Copying these drugs is very hard because the company owns 20 years of patented chemistry and FDA approval, plus a competitor just failed a major trial in mid-2026, which actually helps Alnylam's position. The biggest risk is that nearly all the company's profit comes from one drug called AMVUTTRA, and government price negotiation rules are squeezing its price, which is why the stock fell in summer 2026 even though the business is actually growing fast and making money.

Why
01
AI pressure: None apparent. Tools like NVIDIA BioNeMo speed up siRNA sequence design in the lab but can't replace an approved, manufactured biologic drug. Could AI do the core job? Unlikely.
02
Bigger players: AstraZeneca/Ionis (ATTR-CM), Arrowhead Pharmaceuticals (RNAi platform). AstraZeneca/Ionis's rival ATTR-CM drug failed Phase 3 in July 2026, and Arrowhead's approved RNAi drug targets a different disease, not TTR. Could a giant copy it? No, they are blocked.
03
What protects it. Approved drugs already selling in 70+ countries, plus the broadest siRNA patent estate and 20 years of GalNAc chemistry rivals must design around.
What would change this call
AMVUTTRA net-pricing/gross-margin trends reported at Q2 2026 earnings, July 30, 2026. Would show whether payer or IRA pricing pressure is eroding TTR franchise economics.
Arrowhead files sNDA for plozasiran by end of 2026 and any move into TTR-related indications. Would show whether a rival RNAi platform is expanding into Alnylam's core franchise.
Whether FY2026 TTR revenue lands within the $4.40-4.70B guidance range at year-end results. Would confirm or contradict guidance credibility and demand strength for AMVUTTRA.
Key numbers
  • FY2025 net product revenue $2,987M, up 81% YoY (2026-02-12)
  • Q1 2026 AMVUTTRA/TTR revenue $910M, up 153% YoY (2026-04-30)
  • Stock hit 52-week low $264.21 after analyst downgrade (2026-07-23)
Named risks
  • Heavy revenue concentration in single TTR/AMVUTTRA franchise exposed to payer and IRA pricing pressure. Severity: high
  • Stock fell to 52-week low July 23, 2026 despite strong fundamentals, signaling investor skepticism on margins. Severity: medium
  • Multiple analyst price-target cuts in July 2026 (Jefferies cut from $522 to $330) reflect gross margin concerns. Severity: medium
  • Pipeline readouts (zilebesiran ZENITH, nucresiran) years from completion, leaving near-term growth reliant on one drug class. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
AstraZeneca/Ionisgaining onRival late-stage ATTR-CM trial reportedly failed around July 2026, weakening its position in Alnylam's core franchise
Arrowhead PharmaceuticalscontestingWon first-ever RNAi FDA approval for plozasiran in a different indication (hypertriglyceridemia) in November 2025
Ionis PharmaceuticalscontestingAntisense oligonucleotide leader with Tryngolza approved for FCS in December 2024 and sHTG in mid-2026
Questions people ask
Is Alnylam Pharmaceuticals profitable in 2026?
Yes. Alnylam posted FY2025 net income of $314 million on full-year net product revenues of $2,987 million, up 81% year over year, per its February 12, 2026 earnings release. Q1 2026 net product revenue reached $1.036 billion, up 121% YoY, driven by AMVUTTRA.
Could AI replace Alnylam Pharmaceuticals?
No. AI tools like the June 3, 2026 Inceptive collaboration speed up siRNA candidate design, but Alnylam's revenue comes from six FDA-approved, patent-protected biologic drugs sold in 70+ countries. Manufacturing, regulatory approval, and clinical trust cannot be replicated by AI models alone.
Who is Alnylam Pharmaceuticals' biggest competitor?
In its core ATTR-CM franchise, AstraZeneca partnered with Ionis was the closest rival, but that competing late-stage trial reportedly failed in early-to-mid July 2026, per a July 10, 2026 Yahoo Finance analysis. Arrowhead Pharmaceuticals competes in adjacent RNAi indications after its November 2025 plozasiran approval.
Is Alnylam Pharmaceuticals stock a safe buy in 2026?
It is volatile despite strong fundamentals. Shares hit a 52-week low of $264.21 on July 23, 2026, after JPMorgan, BofA, Truist, and Jefferies all cut price targets that month, citing AMVUTTRA net-pricing pressure and heavy concentration in the TTR franchise.
What is Alnylam's biggest financial risk?
TTR franchise concentration. AMVUTTRA and related TTR products made up the bulk of Alnylam's $910 million Q1 2026 product revenue growth, and analysts flagged payer and IRA drug-pricing pressure on AMVUTTRA net pricing as a reason for July 2026 price-target cuts.
Did Alnylam win FDA approval for AMVUTTRA in ATTR-CM?
Yes. Alnylam's vutrisiran (AMVUTTRA) received U.S. FDA approval for ATTR-CM around March 2025, and by Q1 2026 the drug had generated worldwide clinical experience exceeding 13,000 patient-years, per a May 12, 2026 company presentation.
Timeline
  • 2026-07-23ALNY stock hits 52-week low of $264.21 after multiple analyst price-target cuts
  • 2026-07-14BofA cuts Alnylam price target from $460 to $410
  • 2026-07-10AstraZeneca/Ionis rival ATTR-CM late-stage trial reportedly fails
  • 2026-06-03Alnylam and Inceptive announce AI siRNA design collaboration worth up to $2 billion
  • 2026-05-12Alnylam reports vutrisiran worldwide experience exceeds 13,000 patient-years
  • 2026-04-30Alnylam reports Q1 2026 net product revenue of $1.036 billion, up 121% YoY
  • 2026-02-12Alnylam reports FY2025 net income of $314 million on $2,987 million revenue
  • 2025-12Alnylam invests roughly $250 million in Massachusetts manufacturing capacity
  • 2025-11Arrowhead Pharmaceuticals wins first-ever RNAi FDA approval for plozasiran
  • 2025-10-01First patient dosed in Phase 3 ZENITH trial for zilebesiran with Roche
Head to head
Alnylam Pharmaceuticals vs Ionis Pharmaceuticals
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources